Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;80(4):996-1005.
doi: 10.1111/all.16456. Epub 2024 Dec 26.

Exposure Profiles for the Long-Term Use of Disinfectants and Cleaning Products and Asthma

Affiliations

Exposure Profiles for the Long-Term Use of Disinfectants and Cleaning Products and Asthma

Emilie Pacheco Da Silva et al. Allergy. 2025 Apr.

Abstract

Background: Using disinfectants and cleaning products (DCPs) at home and work is known to influence both the onset and course of asthma, but most epidemiological studies did not consider the multiplicity and correlations of exposures to DCPs. We aimed to identify exposure profiles for the long-term weekly use of DCPs by latent class analysis (LCA) and assess their associations with asthma.

Methods: LCA was conducted on data from 1143 young adults initially recruited in the German centers of Phase II of the International Study of Asthma and Allergies in Childhood (ISAAC) and followed up three times. In our LCA model, we included the use of cleaning sprays, disinfectant sprays, and nonspray disinfection methods, measured at ages 19-24 (first assessment) and 29-34 years (second assessment). Associations between identified exposure profiles and current as well as incident asthma/wheeze were evaluated by logistic regression.

Results: We identified five long-term exposure profiles to DCPs (latent classes): no weekly use of DCPs (55% of participants), use in first assessment (7%), use in second assessment (18%), persistent use (8%), and persistent cleaning sprays use (12%). Compared to "no weekly use," being in the "persistent use" profile was associated with both current asthma (OR = 1.68, 95% CI = [0.48-5.88]) and current wheeze (OR = 1.71, 95% CI = [0.75-3.90]). For incident asthma/wheeze, interval estimates were very wide.

Conclusions: Our study identified five distinct long-term exposure profiles to DCPs. Among those, only a persistent weekly use of multiple DCPs over time seemed to have an adverse effect on asthma. However, large confidence intervals indicate considerable uncertainty.

Keywords: asthma; disinfectants and cleaning products; exposure profiles; latent class analysis; sprays.

PubMed Disclaimer

Conflict of interest statement

E.vM. reports grants from OM Pharma; consulting fees from OM Pharma, AstraZeneca; payment or honoraria from ALK‐Abello Arzneimittel GmbH, AstraZeneca, OM Pharma, and Abbott Laboratories; support for attending meetings and/or travel from Fabio Luigi Massimo Ricciardolo/Contatto S.r.l., Karl‐Landsteiner Private University for Health Sciences, Gordon Research Conferences, Arla, OM Pharma; participation on the BEAMS External Scientific Advisory Board (ESAB) and Abbott Allergy Risk Reduction Advisory Board. E.vM. has Patent No. PCT/EP2019/085016 (barn dust extract for the prevention and treatment of diseases) pending, royalties paid to ProtectImmun for patent EP2361632 (Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders, granted on 19 March 2014), and patents EP1411977 (composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases, granted on April 18, 2007), EP1637147 (stable dust extract for allergy protection, granted on December 10, 2008), and EP1964570 (pharmaceutical compound to protect against allergies and inflammatory diseases, granted on November 21, 2012) licensed to ProtectImmun. Patent EP21189353.2. 2021. von Mutius E, Rankl B, Bracher F, Müller C, Walker A, Hauck SM, Merl‐Pham J, and inventors; PROTEINS IDENTIFIED FROM BARN DUST EXTRACT FOR THE PREVENTION AND TREATMENT OF DISEASES. Patent PCT/US2021/016918. 2021. Martinez FD, Vercelli D, Snyder SA, von Mutius E, Pivniouk V, Marques dos Santos M, and inventors; THERAPEUTIC FRACTIONS AND PROTEINS FROM ASTHMA‐PROTECTIVE FARM DUST. Patent EP21189353.2. 2021. von Mutius E, Rankl B, Bracher F, Müller C, Walker A, Hauck SM, Merl‐Pham J, Adler H, Yildirim A.Ö., Sattler M, Santos Dias Mourao A, Borggräfe J, O'Connor P.D., Plettenburg O, and inventors; PROTEINS IDENTIFIED FROM BARN DUST EXTRACT FOR THE PREVENTION AND TREATMENT OF DISEASES.

C.V. reports a research grant from Boehringer Ingelheim; consulting fees from Sanofi Aventis; and payment or honoraria from Sanofi Aventis, AstraZeneca, and Novartis Pharma.

E.P.D.S., T.W., J. Gerlich, G.W., J. Genuneit, D.N., K.R., and F.F. declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
For each of the four study phases, a box describes the time period of data collection, the age range, and the number of participants at data collection.
FIGURE 2
FIGURE 2
Probabilities of weekly use of DCPs at SOLAR 2 and 3 according to exposure profiles. Each subplot shows the probabilities of weekly use of cleaning sprays, disinfectant sprays, and nonspray disinfection methods with their respective 95% confidence interval at SOLAR 2 and 3 for one latent class. Prevalence of each exposure profile (latent class), with their respective 95% confidence interval, is shown under their label. Numerical values are displayed in Table S3. poLCA calculated an entropy between 2.40 and 2.50 for the models based on the 20 imputed datasets.
FIGURE 3
FIGURE 3
Associations of the identified exposure profiles with current asthma/wheeze and incident asthma/wheeze. LC 1: No weekly use; LC 2: Persistent cleaning sprays use; LC 3: Decreased use; LC 4: Increased use; LC 5: Persistent use. Adjusted odds ratios (ORs) for sex, age, smoking status, study center, and socioeconomic status, presented with their 95% confidence interval [95% CI] were estimated by logistic regression models. Models for current asthma/wheeze at SOLAR 3 were further adjusted for current asthma/wheeze at SOLAR 2, respectively. The arrow on the upper CI means that the value is larger than 10, that is, the x‐axis upper limit. Associations with current asthma were performed on 1003 to 1008 participants (from the 20 imputed datasets) with the remaining ones being excluded due to remittent asthma. Associations with current wheeze were performed on 1143 participants. Associations with incident asthma were performed on 911 to 920 participants (from the 20 imputed datasets), and those with incident wheeze were performed on 860 to 870 participants (from the 20 imputed datasets) with the remaining ones being excluded due to remittent asthma/wheeze, respectively. Participants with current asthma/wheeze were compared to those with no current asthma/wheeze at SOLAR 3. Participants with incident asthma/wheeze were compared to those with no asthma/wheeze from ISAAC Phase 2 to SOLAR 3.

Similar articles

References

    1. Porsbjerg C., Melén E., Lehtimäki L., and Shaw D., “Asthma,” Lancet 401, no. 10379 (2023): 858–873, 10.1016/S0140-6736(22)02125-0. - DOI - PubMed
    1. 2024 GINA Main Report , “Global Initiative for Asthma,” accessed May 17, 2024, https://ginasthma.org/2024‐report/.
    1. Leynaert B., Le Moual N., Neukirch C., Siroux V., and Varraso R., “Environmental Risk Factors for Asthma Developement,” La Presse Médicale 1983 48, no. 3 Pt 1 (2019): 262–273, 10.1016/j.lpm.2019.02.022. - DOI - PubMed
    1. Agache I., Canelo‐Aybar C., Annesi‐Maesano I., et al., “The Impact of Indoor Pollution on Asthma‐Related Outcomes: A Systematic Review for the EAACI Guidelines on Environmental Science for Allergic Diseases and Asthma,” Allergy 17 (2024): 1761–1788, 10.1111/all.16051. - DOI - PubMed
    1. Mwanga H. H., Dumas O., Migueres N., Le Moual N., and Jeebhay M. F., “Airway Diseases Related to the Use of Cleaning Agents in Occupational Settings,” Journal of Allergy and Clinical Immunology S2213‐2198, no. 24 (2024): 214–219, 10.1016/j.jaip.2024.02.036. - DOI - PubMed

MeSH terms